Results 11 to 20 of about 2,025 (170)

The WheelCams on the IDEFIX rover [PDF]

Progress in Earth and Planetary Science
IDEFIX, the Martian Moons eXploration (MMX) mission Phobos rover, will be the first of its kind to attempt wheeled-locomotion on a low-gravity surface.
Naomi Murdoch, Valérian Lalucaa, Cecily Sunday, Simon Tardivel, Jean Bertrand, Nicolas Théret, Damien Vivet, Alice Amsili, Colas Robin, Panos Delton, Alexia Duchene, Quentin Douaglin, Antoine Maillard, Cedric Virmontois, Pierre Vernazza, Laurent Jorda, Olivier Groussin, Hideaki Miyamoto, Jean-Baptiste Vincent, Jessica Flahaut, Jens Biele, Olivier Barnouin, Christine Hartzell, Fabien Buse, Stefan Barthelmes, Stephan Ulamec, Patrick Michel, Julien Baroukh   +27 more
doaj   +2 more sources

Repeated (Weekly) Intra-Articular Injections of Sulfated Galactans Attenuate Cartilage Degeneration in a Rat Model of Osteoarthritis. [PDF]

J Orthop Res
Knee osteoarthritis (OA) is characterized by progressive cartilage degeneration and remains a major cause of joint dysfunction with limited disease‐modifying therapies. This study evaluated the therapeutic potential of sulfated galactans (SG) extracted from Gracilaria fisheri in a rat OA model induced by anterior cruciate ligament transection and ...
Srianake N, Thongsuk A, Desclaux S, Phuagpan T, Sriwong J, Kongchanagul A, Himakhun W, Hemstapat R, Wongprasert K.   +8 more
europepmc   +2 more sources

Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis. [PDF]

JGH Open
ABSTRACT Aims Proton pump inhibitors (PPIs) and potassium‐competitive acid blockers (PCABs) are widely used for acid‐related disorders. Recent studies have raised concerns that acid suppression may alter gut microbiota and drug pharmacokinetics, potentially influencing therapeutic outcomes in patients with inflammatory bowel disease.
Otagiri S, Ito T, Yagisawa K, Sugitani A, Maemoto A.   +4 more
europepmc   +2 more sources

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis

Медицинский совет, 2021
Introduction. Treatment of patients with ulcerative colitis (UC) requires continuous anti-relapse therapy. Mesalazines are the firstline disease-modifying drugs for the treatment of mild to moderate UC to manage exacerbations and to induce and maintain ...
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya   +2 more
doaj   +1 more source

Optimization of approaches to the treatment of mild to moderate ulcerative colitis

Лечащий Врач, 2021
Ulcerative colitis is an autoimmune disease of the colon, manifested by the development of non-specific inflammation of its mucous membrane with a mandatory lesion of the rectum.
S. S. Belous, O. V. Knyazev
doaj   +1 more source

Drugs in focus: Budesonide and its role in paediatric gastrointestinal disorders. [PDF]

J Pediatr Gastroenterol Nutr
Abstract Budesonide is a glucocorticoid with strong topical anti‐inflammatory properties and minimal systemic effects due to extensive first‐pass hepatic metabolism. It is designed for targeted delivery within the gastrointestinal (GI) tract and is available in oral and rectal formulations.
Aziz S, Puoti MG, Assa A, Misak Z, Mas E, Borrelli O, Dolinšek J, Martin-de-Carpi J, Scheers I, Tzivinikos C, Homan M, Strisciuglio C.   +11 more
europepmc   +2 more sources

Frailty Exacerbates Disability in Progressive Multiple Sclerosis. [PDF]

Ann Clin Transl Neurol
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Wicks TR, Wolska A, Ghazal D, Jakimovski D, Weinstock-Guttman B, Burnham A, Bergsland N, Dwyer MG, Remaley AT, Zivadinov R, Ramanathan M.   +10 more
europepmc   +2 more sources

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis

BMC Gastroenterology, 2022
Background Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion.
Ohtaki Yuichiro, Uchiyama Kan, Kamiya Hirotaka, Moriizumi Eri, Yamada Moe, Aoki Yuma, Watanabe Toshimune, Kiryu Sachie, Suzuki Sizuka, Matsumoto Yoshihiro, Ito Zensho, Ohkusa Toshifumi, Koido Shigeo, Saruta Masayuki   +13 more
doaj   +1 more source

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis

Medicina, 2022
A 41-year-old man was treated with prednisolone (PSL) and multimatrix (MMX) mesalamine for remission induction therapy of ulcerative colitis. PSL was tapered due to successful remission induction treatment.
Mimari Kanazawa, Keiichi Tominaga, Akira Kanamori, Takanao Tanaka, Satoshi Masuyama, Shoko Watanabe, Keiichiro Abe, Akira Yamamiya, Kenichi Goda, Atsushi Irisawa   +9 more
doaj   +1 more source

Characterization of Osteoarthritis in a Medial Meniscectomy-Induced Animal Model Using Contrast-Enhanced X-ray Microtomography

Biomedicines, 2020
The aim of this study was to clarify degradation characteristics in each tissue of the knee complex of a medial meniscectomy (MMx)-induced knee osteoarthritis (KOA) animal model using classical methods and an alternative comprehensive evaluation method ...
Takehito Sugasawa, Tomoaki Kuji, Kai Aoki, Koki Yanazawa, Akiko Takenouchi, Makoto Watanabe, Yoshiya Tome, Yoshinori Takeuchi, Yuichi Aita, Naoya Yahagi, Yasuhiro Shishikura, Seiko Ono, Yasuko Yoshida, Yasushi Kawakami, Kazuhiro Takekoshi   +14 more
doaj   +1 more source